drugset / Trial / NCT00271414

A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy

NCT00271414

Phase 3 Completed 53 enrolled Janssen Pharmaceutica N.V., Belgium
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety and clinical utility of Duragesic® 12.5 micrograms/hour (a transdermal patch delivering the narcotic pain-reliever fentanyl) in the treatment of children ages 2 to 12 with continuous pain requiring narcotic pain relief therapy. Pharmacokinetics (fentanyl levels in the bloodstream during treatment) will also be assessed.

Timeline

Start
1999-03
Primary completion
Completion
2001-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 12.5 ug Other

Indications